Objective : To observe the therapeutic effect of Chenxia Liujunzi Wan ( CLW ) for neuroleptic salivation .

目的： 观察陈夏六君子丸治疗抗精神病药流涎副作用的疗效。

This is the largest neuroleptic withdrawal study of Alzheimer's patients and the only long-term one of its type.

这是规模最大的一次关于阿尔兹海默氏病患者神经抑制剂戒断的研究也是同类研究中为期时间最长的。

It was found that the death causes were correlated with the neuroleptic doses, the application of combined drugs, and the body conditions, etc.

发现死因与用药剂量、合并用药、躯体状况等有关。

Neuroleptic malignant syndrome presenting features include: fever altered level of consciousness and "lead-pipe" skeletal muscle rigidity causing rhabdomyolysis.

抗精神病药物恶性症候群会引起意识改变、高烧、“铅管样”肌肉僵直并横纹肌溶解症。

Since the initial report of neuroleptic malignant syndrome (NMS) in 1960, lots of clinical data have been accumulated on the pathogenesis, manifestations and treatment of NMS.

自从1960年首次报道抗精神病药恶性综合征（ NMS）后，大量的临床案例已使人们对于NMS的发病机制、临床表现和治疗有了较深的了解。

Methods: 110 cases with neuroleptic salivation were allocated to two groups randomly, treatment group (56 cases) were given CLW for oral use and control group (54 cases) by artane or phenergan.

方法：将110例因使用抗精神病药致流涎的患者随机分为2组，治疗组56例，口服陈夏六君子丸；对照组54例，使用安坦或非那根治疗。

These initial symptoms can overlap considerably with those of other cardiac and non-cardiac conditions, including neuroleptic malignant syndrome (NMS), which may itself be caused by antipsychotics.

这些始发症状可与其他的心脏和非心脏原因引起的疾病症状相叠加，包括可由抗精神病药物引起的抗精神病药恶性综合征。